Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

673 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Strong association between c-myb and oestrogen-receptor expression in human breast cancer.
Guérin M, Sheng ZM, Andrieu N, Riou G. Guérin M, et al. Oncogene. 1990 Jan;5(1):131-5. Oncogene. 1990. PMID: 2181374
Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type.
Prost S, Lê MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guérin M, Riou G. Prost S, et al. Among authors: guerin m. Int J Cancer. 1994 Sep 15;58(6):763-8. doi: 10.1002/ijc.2910580602. Int J Cancer. 1994. PMID: 7927865
[Analysis of the expression of the oncogene c-myc in human breast adenocarcinoma].
Guérin M, Lacombe MJ, Riou G. Guérin M, et al. C R Acad Sci III. 1985;301(20):833-8. C R Acad Sci III. 1985. PMID: 3938309 French.
[The expression of c-myb is strongly associated with the presence of estrogen and progesterone receptors in breast cancer].
Guerin M, Barrois M, Riou G. Guerin M, et al. C R Acad Sci III. 1988;307(20):855-61. C R Acad Sci III. 1988. PMID: 2907731 French.
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M, Barrois M, Terrier MJ, Spielmann M, Riou G. Guérin M, et al. Oncogene Res. 1988;3(1):21-31. Oncogene Res. 1988. PMID: 2905033
c-Ha-ras-1 polymorphism in human breast carcinomas: evidence for a normal distribution of alleles.
Sheng ZM, Guerin M, Gabillot M, Spielmann M, Riou G. Sheng ZM, et al. Among authors: guerin m. Oncogene Res. 1988 Feb;2(3):245-50. Oncogene Res. 1988. PMID: 2897104
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance.
Guérin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G. Guérin M, et al. Int J Cancer. 1989 Feb 15;43(2):201-8. doi: 10.1002/ijc.2910430205. Int J Cancer. 1989. PMID: 2563719
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, Provansal M, Camerlo J, Sabatier R, Bertucci F, Charafe-Jauffret E, Hervieu A, Extra JM, Viens P, Lokiec F, Boher JM, Gonçalves A. Guerin M, et al. Eur J Cancer. 2017 Nov;86:28-36. doi: 10.1016/j.ejca.2017.08.025. Epub 2017 Sep 23. Eur J Cancer. 2017. PMID: 28950146 Clinical Trial.
Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, Paciencia-Gros M, Poizat F, Bentobji M, Azario-Cheillan F, Walz J, Salem N, Brunelle S, Moretta A, Olive D. Pasero C, et al. Among authors: guerin m. Cancer Res. 2016 Apr 15;76(8):2153-65. doi: 10.1158/0008-5472.CAN-15-1965. Epub 2016 Apr 5. Cancer Res. 2016. PMID: 27197252
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
Guerin M, Sabatier R, Gonçalves A. Guerin M, et al. Bull Cancer. 2015 Apr;102(4):390-7. doi: 10.1016/j.bulcan.2015.02.007. Epub 2015 Mar 16. Bull Cancer. 2015. PMID: 25790739 French.
673 results
Jump to page
Feedback